ArticleOncogene2022

DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.

Sk Kayum Alam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.